NCT05578053View on ClinicalTrials.gov

Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer

RecruitingOBSERVATIONAL
Enrollment

420

Participants

Timeline

Start Date

September 13, 2024

Primary Completion Date

December 1, 2028

Study Completion Date

December 1, 2030

Conditions
Breast Cancer
Interventions
DRUG

Dalpiciclib

a new, orally administered, selective CDK4/6 inhibitor

Trial Locations (1)

050011

RECRUITING

The Fourth hospital of Hebei University, Shijiazhuang

All Listed Sponsors
lead

Hebei Medical University Fourth Hospital

OTHER